Very short term dehydroepiandrosterone treatment in female adrenal failure: impact on carbohydrate, lipid and protein metabolism

Jens Juel Christiansen, Claus Højbjerg Gravholt, Sanne Fisker, Niels Møller, Marianne Andersen, Birgit Svenstrup, Paul Bennett, Per Ivarsen, Jens Sandahl Christiansen and Jens Otto Lunde Jørgensen

Medical Department M, Århus Sygehus, Århus University Hospital, Århus, Denmark, 1Department of Endocrinology, Odense University Hospital, Odense, Denmark, *Statens Serum Institut, Copenhagen, Denmark, and 3Institute of Experimental Clinical Research, Århus University, Århus, Denmark

(Correspondence should be addressed to C H Gravholt, Medical Department M, Århus Sygehus, Århus University Hospital, DK 8000 C, Denmark; Email: ch.gravholt@dahdnet.dk)

Abstract

Objective: In female adrenal insufficiency, dehydroepiandrosterone (DHEA) secretion is impaired and circulating androgen levels are severely reduced. We wanted to analyse the acute effects of physiological DHEA substitution on substrate metabolism.

Design: We studied nine females with adrenal insufficiency after 9 days of oral DHEA replacement (50 mg/day) in a double-blind, placebo-controlled crossover study.

Methods: Whole body and regional substrate metabolism was assayed in the basal state and during a euglycemic hyperinsulinemic glucose clamp by means of isotope dilution techniques (glucose, phenylalanine, tyrosine), indirect calorimetry and in situ lipolysis (microdialysis technique).

Results: DHEA treatment normalized the levels of all androgens. Basal and insulin-stimulated total energy expenditure and rates of protein, lipid and glucose oxidation were unaffected by DHEA. Whole body turnover of glucose and protein were also unaffected by DHEA. Forearm breakdown of protein was reduced by insulin to the same extent after placebo and DHEA. Insulin sensitivity as expressed by the glucose infusion rate during the euglycemic clamp was similar after placebo and DHEA. Finally, the interstitial release of glycerol in adipose tissue was not significantly influenced by DHEA.

Conclusions: Short-term oral DHEA replacement in women with adrenal insufficiency was not associated with measurable changes in total or regional substrate metabolism.
exchange of metabolites and in situ lipolysis by means of microdialysis in adipose tissues.

**Subjects and methods**

**Study population**

The study population comprised nine females with adrenal failure (eight with Addison’s disease and one monotonre ACTH failure) and a mean age of 42 years (range 22–54), with a mean duration of disease of 6.9 years (1–16 years). All participants were on stable hydrocortisone (15–30 mg/day) and fluorocortisone (0–0.20 mg/day) treatment. One of two postmenopausal patients was treated with vaginal estradiol (vaginal capsules containing 25 μg). Three of seven naturally mensturating patients included thyroid hormones (two patients), calcium and vitamin D (three patients), bisphosphonate (one patient) and hydroxyco-balamin (one patient). None of the participants had previously received DHEA or androgens and none of them had diabetes. They were studied during the early follicular phase (day 5–10) of their regular cycle or in the corresponding phase of an oral contraceptive cycle induced by cortisol. The protocol was approved by the Århus County Ethical Scientific Committee (no. 1998/4375). All participants gave informed oral and written consent.

**Study protocol**

The patients were treated for 9 days with a daily morning dose of DHEA (50 mg) or placebo in a double-blind, randomized, placebo-controlled crossover design. Each treatment period was separated by a wash-out period of at least 2 months. During the treatment period, participants continued normal daily living. At day 8, participants were admitted to the laboratory for clinical evaluation. During this period hydrocortisone substitution (Solucortef; Pharmacia, Stockholm, Sweden) was administered as a continuous infusion in a hand vein. The infusion rate was modified according to Hangaard et al. (11) (0800 – 1400 h, 0.026 mg/kg per h; 1400 – 0200 h, 0.014 mg/kg per h; 0200 – 1400 h, 0.026 mg/kg per h). Three standardized meals (total 2000 kcal (15% protein, 50% carbohydrate and 35% fat)) were served (0830, 1200 and 1800 h) and thereafter patients fasted. Inter-meal snacks and caloric beverages were avoided. Starting at 0800 h a 24-h hormonal profile was obtained and urine production was collected. Blood samples were drawn in a contralateral cubital vein every 20 min for growth hormone (GH) measurements (previously published (12)) and every 60 min for blood glucose and other hormones. At 1500 h two microdialysis catheters were placed in abdominal and femoral subcutaneous adipose tissue respectively. On day 9, fuel metabolism was estimated during fasting (basal period) and during meal simulation by means of insulin and amino acid stimulation (clamp period) (Fig. 1), and all data presented are from this study day. One catheter was placed retrogradely in a deep antecubital vein and one catheter was inserted retrogradely in a heated contralateral dorsal hand vein, allowing collection of venous blood draining the forearm muscle and oxygenated blood from digital capillary shunting respectively. Criteria for correct positioning were oxygen saturation below 70% and above 91% respectively. A third catheter was placed anterogradely in a cubital vein of the heated hand for infusions. The study was conducted and monitored according to the International Conference on Harmonisation – Good Clinical Practice (GCP) guidelines (The GCP Unit, Århus University Hospital). The study drug was produced according to Good Manufacturing Practise (GMP) in a licensed laboratory (Terapharm, Katwijk, The Netherlands). Raw materials fulfilled the requirements of the European Pharmacopea (edn 3). Final analyses document the tests corresponding to the requirements for capsules in the European Pharmacopea. That means uniformity of content, uniformity of mass and disintegration of capsules. According to the analysis certificate the results were: assay 101.5% (95 –105%), mean weight variation 410.4 ± 3.6 mg (401 – 419 mg) and disintegration 3 min (<15 min). Figures in parentheses indicate the requirements of the law.

**Tracers and clamp**

At 0800 h priming doses of [3-3H]glucose (20 μCi; New England Nuclear, Boston, MA, USA) and L-[15N]phenylalanine (0.7 mg/kg), L-[2H4]tyrosine (0.5 mg/kg) and L-[15N]tyrosine (0.3 mg/kg) (Cambridge Isotope Laboratories, Inc., Andover, MA, USA) were given to accomplish an early plateau. A continuous infusion of [3-3H]glucose (20 μCi/h), L-[15N]phenylalanine (0.7 mg/kg/h) and [3-3H]glucose (20 μCi/h) was started (Fig. 1). L-[15N]phenylalanine was administered as a continuous infusion in a hand vein. The infusion rate was modified according to Hangaard et al. (11) (0800 – 1400 h, 0.026 mg/kg per h; 1400 – 0200 h, 0.014 mg/kg per h; 0200 – 1400 h, 0.026 mg/kg per h). Three standardized meals (total 2000 kcal (15% protein, 50% carbohydrate and 35% fat)) were served (0830, 1200 and 1800 h) and thereafter patients fasted. Inter-meal snacks and caloric beverages were avoided. Starting at 0800 h a 24-h hormonal profile was obtained and urine production was collected. Blood samples were drawn in a contralateral cubital vein every 20 min for growth hormone (GH) measurements (previously published (12)) and every 60 min for blood glucose and other hormones. At 1500 h two microdialysis catheters were placed in abdominal and femoral subcutaneous adipose tissue respectively. On day 9, fuel metabolism was estimated during fasting (basal period) and during meal simulation by means of insulin and amino acid stimulation (clamp period) (Fig. 1), and all data presented are from this study day. One catheter was placed retrogradely in a deep antecubital vein and one catheter was inserted retrogradely in a heated contralateral dorsal hand vein, allowing collection of venous blood draining the forearm muscle and oxygenated blood from digital capillary shunting respectively. Criteria for correct positioning were oxygen saturation below 70% and above 91% respectively. A third catheter was placed anterogradely in a cubital vein of the heated hand for infusions. The study was conducted and monitored according to the International Conference on Harmonisation – Good Clinical Practice (GCP) guidelines (The GCP Unit, Århus University Hospital). The study drug was produced according to Good Manufacturing Practise (GMP) in a licensed laboratory (Terapharm, Katwijk, The Netherlands). Raw materials fulfilled the requirements of the European Pharmacopea (edn 3). Final analyses document the tests corresponding to the requirements for capsules in the European Pharmacopea. That means uniformity of content, uniformity of mass and disintegration of capsules. According to the analysis certificate the results were: assay 101.5% (95 –105%), mean weight variation 410.4 ± 3.6 mg (401 – 419 mg) and disintegration 3 min (<15 min). Figures in parentheses indicate the requirements of the law.
(0.7 mg/kg per h) and t-[^3]H_4 tyrosine (0.5 mg/kg per h) was started and maintained for 6 h. Tracer solutions were prepared according to GMP guidelines by the hospital pharmacy (Aarhus University Hospital). After 3 h an intravenous infusion of insulin (Actrapid: Novo Nordisk, Copenhagen, Denmark) and amino acid (Glavanin; Fresenius Kabi AB, Uppsala, Sweden) was commenced. Glucose was infused at a variable rate to ensure euglycemia according to frequent measurement of plasma glucose concentrations.

**Microdialysis and calculations**

Microdialysis fibers (CMA 60 microdialysis catheter; CMA, Stockholm, Sweden) were placed in abdominal and femoral subcutaneous adipose tissue. Immediately after placement, fibers were perfused at a rate of 1 μl/min (CMA-107 perfusion pump; CMA, Stockholm). To the perfusion fluid (Ringer chloride, T1; CMA, Stockholm: Na^+ 147 mmol/l; K^+ 1.4 mmol/l; Ca^{2+} 2.3 mmol/l; Cl^- 156 mmol/l; pH 6; osmolality, 290 mosmol/kg) was added a small amount of [^3]H glycerol in order to measure the relative recovery by an internal reference method (13). Samples were collected every hour from 2100 to 1400 h. An automated spectrophotometric kinetic enzymatic analyzer (CMA 600; CMA, Solna, Sweden) was used for duplicate measurements of glycerol, glucose, urea and lactate in the microdialysate. Changes in interstitial glycerol concentration were used as an index of lipolysis (14).

**Blood flow measurements**

The subcutaneous adipose tissue blood flow in the abdominal and femoral region in which dialysis was performed was measured by the local ^133Xe washout method (15). In short, 3.7 MBq (0.1 ml) ^133Xe was injected subcutaneously in the abdomen and femur. Disappearance of ^133Xe was continuously measured starting 30 min after injection using an NaI detector (Mediscint; Oakfield Instruments Ltd, Workingham, Berkshire, UK) as previously described (16). The tissue/blood partition coefficient was corrected for skinfold thickness as described by Bulow et al. (17). Forearm blood flow was determined by means of venous occlusion plethysmography.

**Indirect calorimetry**

Indirect calorimetry (Deltatrac Metabolic Monitor; Datex, Helsinki, Finland) was performed for 30 min. The initial 5 min were used for acclimatization, and calculations of respiratory quotient and resting energy expenditure (REE) were based on mean values of 25 measurements of 1 min each. Likewise, rates of protein lipid and glucose oxidation were estimated corrected for urinary excretion of urea (18). Net non-oxidative glucose disposal was calculated by subtraction of glucose oxidation from the isotopically assayed total glucose disposal.

**Protein and glucose kinetics**

Whole body phenylalanine kinetics were estimated from the equations of Thompson et al. (19). Regional phenylalanine kinetics were estimated as previously described (20). Phenylalanine flux (Q_p) and tyrosine flux (Q_t) were calculated as follows: Q_flux = i/(E_i/E_p) - 1 in which i is the rate of tracer infusion (μmol/kg per min), and E_i and E_p are enrichment of the tracer infused and plasma enrichment of the tracer at isotopic plateau respectively.

The rate of phenylalanine conversion to tyrosine (I_p) was calculated as follows: I_p = Q_t × ([^15N]Tyr_ei/[^15N]Phe_ei) × (Q_p/(I_p + Q_p)) where [^15N] Tyr_ei and [^15N]Phe_ei are the isotopic enrichments of the respective tracers in plasma and I_p is the infusion rate of [^15N]phenylalanine (μmol/kg per h). Protein synthesis was calculated by subtracting I_p from Q_p, since phenylalanine is irreversibly lost either by conversion into tyrosine or by incorporation into protein.

In the forearm study, phenylalanine balance (PheBal) was calculated as follows: PheBal = (Phe_A - Phe_V) × F in which Phe_A and Phe_V are phenylalanine concentrations in arteries and veins and F is bloodflow.

Regional protein breakdown represented by phenylalanine rate of appearance (RaPhe) was calculated as follows (21) RaPhe = Phe_A(Phe_EA/Phe_EV) - 1) × F in which Phe_EA and Phe_EV represent phenylalanine isotopic enrichment in arteries and veins.

Local rate of disappearance (Rd) was calculated as RdPhe = PheBal + RaPhe.

The specific activity of tritiated glucose was measured as described (22). Rates of appearance (Ra) and Rd of glucose were calculated using Steele’s equation for non-steady state, and a pool fraction of 0.65 was used. Endogenous glucose production during the clamp was calculated by subtracting the rate of glucose infusion (M value) from glucose Ra, as determined isotopically. t-[^15N]phenylalanine, t-[^3]H_4 tyrosine and t-[^15N]tyrosine were measured as their t-butyldimethylsilyl ether derivatives under electron ionization conditions (20). Plasma concentrations of amino acids were determined by an HPLC system (Bio-Tek Kontron, Series 525 and 465, fluorescence detector SFM25, Kontron Instruments, Milan, Italy) with precolumn O-phthalaldehyde derivatization. In addition, concentrations of phenylalanine and tyrosine were measured by mass spectrometry using t-[^3]H_4 phenylalanine and t-[^13]C_6 tyrosine as internal standards respectively (20). Plasma glucose levels were measured in duplicate immediately after sampling on a glucose analyzer (Beckman Instruments, Palo Alto, CA, USA).

**Hormone assays**

Plasma glucagon and serum C-peptide were measured by radioimmunassays (Immunocor, Stillwater, MN, USA). Serum insulin-like growth factor (IGF)-1 was measured by an in-house non-competitive time-resolved
immunofluorometric assay (23). Insulin was determined by a commercial enzyme-linked immunosorbent assay (DAKO, Glostrup, Denmark). Blood levels of alanine, glycerol, 3-hydroxybutyrate and lactate were assayed with an automated fluorometric method (24). Urea excretion in urine was determined by an indophenol method and serum urea by a commercial kit (COBAS INTEGRA; Roche, Hvidovre, Denmark). Cortisol was measured by an automated chemiluminescence system (Chiron Diagnostics, Fernwald, Germany). Free fatty acids (FFA) were determined by a colorimetric method employing a commercial kit (Wako Chemicals, Neuss, Germany). Total and free hormone concentrations of thyroxine (T₄) and tri-iodothyronine (T₃) were measured in serum as previously described (25), while thyrotropin (TSH) was measured in a solid-phase, two-site chemiluminescent enzyme immunometric assay (IMMULITE; DPC, Los Angeles, CA, USA). Androgens, estrogens and sex hormone-binding globulin (SHBG) were analysed as described (26). Mean and normal range (in parentheses), and inter- and intra-assay coefficients of variation respectively were as follows: SHBG: 83 (41–170) nmol/l, 7.5%, 5.2%; testosterone: 1.00 (0.55–1.80) nmol/l, 13.8%, 8.2%; free testosterone: 0.014 (0.006–0.034) nmol/l, 6.4%, 4.7%; dihydrotestosterone (DHT): 0.50 (0.25–1.20) nmol/l, 11.0%, 9.1%; α4-androstenedione: 4.7 (2.4–8.9) nmol/l, 11.4%, 9.4%; DHEA: 5.5 (1.4–12.5) nmol/l, 11.5%, 8.5%; DHES sulphate (DHEAS): 4500 (1200–9500) nmol/l, 11.5%, 8.5%; 17β-oestradiol: 120 (<40–400) pmol/l, 10.5%, 7.4%; estrone: 140 (70–270) pmol/l, 9.6%, 7.0%.

Statistical analysis

As appropriate for parametric and non-parametric data, measurements are expressed as means±S.E.M. or median and range, and comparisons were done with Student’s paired t-test or Wilcoxon signed rank test. We were not able to perform a power analysis prior to performing the study because of the lack of data in the literature regarding the impact of DHEA treatment on the measured parameters. We therefore chose n = 9, since in previous studies with the same methodology we have found a clinically significant impact of short-term interventions. Significance levels less than 5% were considered significant.

Results

Sex hormones

Baseline androgen values following DHEA treatment (placebo vs DHEA (median, range); DHEA: 1.55 (0.39–3.99) vs 5.16 (2.2–11.42), (P = 0.011); DHEAS: 99 (99–440) vs 2800 (1100–8300), (P = 0.008); androstenedione: 1.39 (0.37–3.07) vs 2.52 (0.19–4.18), (P = 0.021); DHT: 0.245 (0.175–0.385) vs 0.46 (0.19–0.90), (P = 0.015); testosterone: 0.46 (0.26–0.78) vs 0.82 (0.38–1.32), (P = 0.011); free testosterone: 0.0075 (0.0025–0.009) vs 0.01 (0.01–0.02), (P = 0.018); DHEAS/testosterone ratio (341±65 vs 4379±671, (P < 0.001)) (Fig. 2). Estradiol (nmol/l) did not change significantly (84.5 (39–420) vs 160 (39–320), (P = 0.612)).

Microdialysis

Interstitial concentrations in subcutaneous fat of glycerol are shown in Fig. 3. No effect of DHEA treatment was seen (placebo vs DHEA, glycercer area under the curve (AUC) (µmol/l), abdominal: 351±44 vs 314±31, (P = 0.456), femoral: 300±50 vs 302±54, (P = 0.959)). Nor did DHEA induce changes in other interstitial metabolites (lactate and glucose, data not shown). Adipose tissue blood flow did not differ between the two treatments (data not shown).

Glucose, circulating hormones and metabolites

Twenty-four hour profiles of glucose, insulin, cortisol and IGF-binding protein (IGFBP)-1 were very similar under the two conditions (glucoseAUC: 5.1±0.1 vs 5.1±0.1 µmol/l per h, (P = 0.922); insulinAUC: 120±20 vs 126±18 pmol/l per h, (P = 0.357); cortisolAUC 270±50 vs 278±53 (mmol/l per h), (P = 0.630); IGFBP-1AUC 1.67±0.17 vs 1.88±0.32 (µg/l per h), (P = 0.372)) (Fig. 4). During the experiment, day 9 levels of circulating hormones were similar between treatments both during fasting and during insulin and amino acid stimulation (clamp) (Table 1). Arterial concentrations of alanine, lactate, glycerol, 3-hydroxybutyrate and FFAs are shown in Table 2. DHEA treatment did not modulate these circulating metabolites in either arterial or venous blood, or as regards the arterial to venous difference (data not shown).

Whole body protein metabolism

Plasma concentrations of amino acids (Table 3) and serum urea were similar in both conditions (placebo vs DHEA, urea (mmol/l): 4.89±0.26 vs 4.80±0.26, (P = 0.625)). Twenty-four hour urinary urea excretion rate (UER) and UER during fasting (basal) and during insulin and amino acid stimulation (clamp) were unaffected by DHEA treatment (UER24 h: 14.3±1.0 vs 14.2±1.1 mmol/h, (P = 0.963); UERbasal: 16.4±5.3 vs 16.1±3.8 mmol/h, (P = 0.961); UERclamp: 18.8±1.8 vs 15.2±2.0 mmol/h, (P = 0.224)). Phenylalanine and tyrosine fluxes remained unaffected by DHEA treatment in both the basal and clamp period (Table 3). Neither phenylalanine conversion to tyrosine, representing amino acid breakdown, nor protein
synthesis (phenylalanine disposal not accounted for by phenylalanine conversion to tyrosine) were significantly influenced by DHEA treatment.

**Forearm protein metabolism**

Forearm blood flow decreased under DHEA treatment in the basal period, but this was not significant during insulin stimulation. Forearm muscle exhibited an equal net release of phenylalanine during the basal period in both treatment conditions (Table 3). Insulin and amino acid stimulation converted this into a positive balance with no significant influence of DHEA treatment. Muscle protein breakdown, represented by phenylalanine rate of appearance, was equal in both the basal and clamp period. Incorporation of phenylalanine into muscle, represented by the phenylalanine rate of disappearance, was also not affected by active treatment.

**Indirect calorimetry and glucose turnover**

REE was not altered by DHEA treatment (placebo vs DHEA: REEbasal: 1263 ± 54 vs 1282 ± 48 kcal/24 h, \(P = 0.602\); REEclamp: 1466 ± 59 vs 1422 ± 47 kcal/24 h, \(P = 0.999\)), and fuel oxidation was similarly distributed between protein (ProtOx), glucose (GlucOx) and lipid (LipOx) (placebo vs DHEA: ProtOxbasal: 407 ± 130 vs 399 ± 95 kcal/24 h, \(P = 0.96\); ProtOxclamp: 465 ± 43 vs 376 ± 50 kcal/24 h \(P = 0.22\); GlucOxbasal: 454 ± 90 vs 418 ± 53 kcal/24 h, \(P = 0.70\); GlucOxclamp: 640 ± 50 vs 763 ± 76 kcal/24 h, \(P = 0.28\); LipOxbasal: 403 ± 94 vs 466 ± 85 kcal/24 h, \(P = 0.67\); LipOxclamp: 360 ± 83 vs 283 ± 85 kcal/24 h, \(P = 0.51\)). Endogenous glucose production (EGP), glucose rate of disappearance (GlcRd) and non-oxidative glucose disposal (Nonox disp) were also similar under the two conditions (placebo vs DHEA: EGPbasal: 0.105 ± 0.0071 vs 0.104 ± 0.0119 mg/kg per min, \(P = 0.746\); EGPclamp: -1.922 ± 0.2083 vs -1.988 ± 0.2300 mg/kg per min, \(P = 0.952\); GlcRdbasal: 0.1070 ± 0.0082 vs 0.1053 ± 0.0115 mg/kg per min, \(P = 0.620\); GlcRdclamp: 0.1769 ± 0.0130 vs 0.1727 ± 0.0131 mg/kg per min, \(P = 0.147\); Nonox dispbasal: 0.55 ± 0.48 vs 0.76 ± 0.31 mg/kg per min, \(P = 0.671\); Nonox dispclamp: 1.25 ± 0.20 vs 1.01 ± 0.31 mg/kg per min, \(P = 0.647\)). DHEA treatment did not alter insulin sensitivity (M value) (placebo vs DHEA: 2.17 ± 0.17 vs 2.15 ± 0.23 mg/kg per min, \(P = 0.942\)).

**Figure 2** Circulating androgens before and during DHEA treatment. Individual values are depicted, with a line connecting baseline data and during DHEA treatment. Upper and lower limits of normal reference values for women are depicted by the broken lines.
Discussion

In the present study we have evaluated the short-term effects of physiological DHEA replacement in women with adrenal failure on substrate metabolism in the basal state as well as during infusion of insulin, glucose and amino acids. We found no significant effects of DHEA treatment. During both study days an identical cortisol substitution was given as an infusion to avoid a confounding effect of differential absorption from the gut of orally given cortisol tablets. These data suggested that acute alterations in adrenal androgens play only a limited role in the physiological regulation of substrate metabolism in women. Testosterone is believed to be the primary anabolic androgen in muscle (27) acting both through direct effects on a nuclear androgen receptor, and through indirect effects on transcription factors and mediators that modulate gene expression (28). Upon short-term physiological androgen substitution with DHEA in this study, we induced a twofold increase in DHT and testosterone but observed neither increased muscle protein synthesis nor reduced amino acid release, and we found no evidence of stimulated subcutaneous fat mobilization estimated by in situ glycerol release. DHEA substitution in female adrenal failure during 3 (29) and 4 months (6) did not influence body composition, but after 6 and 12 months an increase in lean body mass was detected (9), though this was only seen in the open labeled part of

Figure 3 Effects of DHEA (♦) and placebo (○) treatment on 17-h interstitial glycerol dynamics, as an index of subcutaneous fat lipolysis, measured with an (A) abdominal and (B) femoral microdialysis catheter. The values presented are means ± S.E.M.

Figure 4 Effects of DHEA (♦) and placebo (○) treatment in female adrenal failure on 24-h serum profile of (A) glucose, (B) insulin and (C) cortisol. The values presented are means ± S.E.M.
the trial. It therefore seems doubtful that physiological DHEA supplementation produces clinically relevant anabolic effects in women. Testosterone administration in female to male transsexuals increases thigh muscle area and reduces subcutaneous fat deposition (30), diminishes fat cell size and increases basal lipolysis estimated by in vitro glycerol release (31). In men, 5 days of testosterone or oxandrolone treatment (32, 33) but not androstendione (34) increases muscle protein synthesis. In hypoandrogenic men, body fat is increased (35) and, during long-term androgen replacement, muscle protein synthesis (36) and muscle mass increase concomitantly with a reduction in body fat (35).

Table 1 Effects of DHEA and placebo treatment, in female adrenal failure, on circulating hormones, during fasting condition and during insulin and amino acid stimulation.

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>DHEA</th>
<th>P</th>
<th>Placebo</th>
<th>DHEA</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cortisol (nmol/l)</td>
<td>286±39</td>
<td>284±44</td>
<td>0.807</td>
<td>291±44</td>
<td>302±42</td>
<td>0.498</td>
</tr>
<tr>
<td>Insulin (pmol/l)</td>
<td>51.7±11.2</td>
<td>47.4±7.2</td>
<td>0.414</td>
<td>315.7±50.8</td>
<td>286.0±52.9</td>
<td>0.916</td>
</tr>
<tr>
<td>IGF-I (µg/l)</td>
<td>172.1±8.3</td>
<td>176.3±7.3</td>
<td>0.661</td>
<td>172.7±9.3</td>
<td>170.9±8.7</td>
<td>0.426</td>
</tr>
<tr>
<td>IGFBP-1 (µg/l)</td>
<td>3.61±0.54</td>
<td>4.31±0.67</td>
<td>0.341</td>
<td>2.85±0.34</td>
<td>3.04±0.47</td>
<td>0.321</td>
</tr>
<tr>
<td>TSH (µmol/ml)</td>
<td>1.67±0.30</td>
<td>1.44±0.29</td>
<td>0.179</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T3 (nmol/l)</td>
<td>1.19±0.07</td>
<td>1.18±0.05</td>
<td>0.786</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T4 (nmol/l)</td>
<td>79.7±4.8</td>
<td>78.1±3.3</td>
<td>0.564</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 2 Effects of placebo and DHEA treatment on arterial metabolite concentrations, during fasting and during insulin and amino acid stimulation.

<table>
<thead>
<tr>
<th>Concentrations (µmol/l)</th>
<th>Placebo</th>
<th>DHEA</th>
<th>P</th>
<th>Placebo</th>
<th>DHEA</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alanine</td>
<td>246±13</td>
<td>263±19</td>
<td>0.537</td>
<td>504±20</td>
<td>500±22</td>
<td>0.850</td>
</tr>
<tr>
<td>Lactate</td>
<td>591±51</td>
<td>628±77</td>
<td>0.575</td>
<td>605±23</td>
<td>647±24</td>
<td>0.284</td>
</tr>
<tr>
<td>Glycerol</td>
<td>64.2±5.9</td>
<td>65.6±9.2</td>
<td>0.877</td>
<td>20.2±2.3</td>
<td>25.3±5.5</td>
<td>0.233</td>
</tr>
<tr>
<td>3-Hydroxybutyrate</td>
<td>142.4±37.2</td>
<td>170.2±52.9</td>
<td>0.326</td>
<td>2.4±0.5</td>
<td>2.6±0.8</td>
<td>0.531</td>
</tr>
<tr>
<td>FFA</td>
<td>0.575±0.08</td>
<td>0.588±0.088</td>
<td>0.818</td>
<td>0.071±0.018</td>
<td>0.075±0.025</td>
<td>0.611</td>
</tr>
</tbody>
</table>

Table 3 Effects of DHEA and placebo treatment in female adrenal failure on phenylalanine and tyrosine fluxes in both whole body and forearm.

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>DHEA</th>
<th>P</th>
<th>Placebo</th>
<th>DHEA</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whole body</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Qphe (µmol/kg per h)</td>
<td>37.16±2.59</td>
<td>38.85±1.99</td>
<td>0.308</td>
<td>62.25±2.04</td>
<td>64.21±2.92</td>
<td>0.981</td>
</tr>
<tr>
<td>Endogenous Qphe (µmol/kg per h)</td>
<td></td>
<td></td>
<td></td>
<td>24.28±2.05</td>
<td>26.25±2.92</td>
<td>0.981</td>
</tr>
<tr>
<td>Total Qtyr (µmol/kg per h)</td>
<td>32.83±1.75</td>
<td>32.68±0.92</td>
<td>0.914</td>
<td>45.00±2.00</td>
<td>46.09±1.27</td>
<td>0.878</td>
</tr>
<tr>
<td>Endogenous Qtyr (µmol/kg per h)</td>
<td></td>
<td></td>
<td></td>
<td>31.70±2.00</td>
<td>32.79±1.27</td>
<td>0.878</td>
</tr>
<tr>
<td>Qpt (µmol/kg per h)</td>
<td>4.28±0.18</td>
<td>4.00±0.22</td>
<td>0.394</td>
<td>8.93±0.73</td>
<td>7.47±0.82</td>
<td>0.281</td>
</tr>
<tr>
<td>Protein synthesis (µmol/kg per h)</td>
<td>32.88±2.57</td>
<td>34.85±2.07</td>
<td>0.220</td>
<td>53.32±2.44</td>
<td>56.74±3.27</td>
<td>0.678</td>
</tr>
<tr>
<td>Forearm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BalPhe (nmol/100 ml per min)</td>
<td>−1.19±0.66</td>
<td>−1.40±0.42</td>
<td>0.794</td>
<td>0.31±1.75</td>
<td>1.39±0.67</td>
<td>0.737</td>
</tr>
<tr>
<td>RaPhe (nmol/100 ml per min)</td>
<td>1.62±0.95</td>
<td>2.51±1.31</td>
<td>0.287</td>
<td>2.56±1.08</td>
<td>2.78±0.88</td>
<td>0.683</td>
</tr>
<tr>
<td>RdPhe (nmol/100 ml per min)</td>
<td>0.43±0.61</td>
<td>1.11±1.14</td>
<td>0.354</td>
<td>2.87±2.23</td>
<td>4.17±0.71</td>
<td>0.578</td>
</tr>
<tr>
<td>Flow (ml/100 per ml per min)</td>
<td>2.59±0.51</td>
<td>1.84±0.21</td>
<td>0.005</td>
<td>2.23±0.38</td>
<td>1.93±0.22</td>
<td>0.384</td>
</tr>
</tbody>
</table>
In females, reciprocal actions of DHEA and testosterone on insulin have been proposed, with testosterone showing a positive correlation to stimulated insulin levels and negative to indices of insulin receptor binding, and DHEA showing the opposite correlations (37). Comparing classical with non classical 21-hydroxylase deficiency (38) and congenital adrenal hyperplasia with polycystic ovary syndrome (39), the observed difference in insulin sensitivity has been explained by the DHEAS to testosterone ratio. Amelioration of insulin resistance in diabetes with DHEA in one female patient has been reported (40). In the present study, the DHEA to testosterone ratio was over tenfold increased within the same person, without subsequent changes in glucose turnover and insulin sensitivity, indicating that it is unlikely that physiological replacement with DHEA influences glucose metabolism and insulin sensitivity. Our examination of carbohydrate metabolism and insulin sensitivity corroborates previous more long-term studies. DHEA treatment of women with adrenal insufficiency for 3 (29), 4 (6) and 12 months (9) did not affect fasting insulin and glucose levels. DHEA treatment (50–200 mg) for 3 months in same model was not followed by alterations in insulin sensitivity estimated by clamp (29) and treatment for 12 weeks in a gender-mixed population did not affect insulin sensitivity estimated by homeostasis model assessment (7). So far no receptor for DHEA has been localized. In a recent paper (41), an endothelial plasma membrane receptor (41) activating G-proteins and endothelial nitric oxide synthase has been suggested. This could be the background for the observed decrease in forearm blood flow during DHEA treatment. Further investigation is needed to specify the physiological role of DHEA on the cardiovascular system.

In spite of the corrected circulating androgen status in our study population we did not detect any physiological effects by the applied methodologies. The subjects were studied after only short-term treatment in order to detect direct effects on substrate metabolism prior to possible changes in body composition and physical fitness. Indeed, 5 days of testosterone treatment has previously been shown to stimulate protein synthesis in men (32, 33). It remains possible, however, that more prolonged study would have translated into significant effects. Nevertheless, previous studies of longer duration have been unable to detect effects on glucose metabolism and insulin sensitivity, as mentioned above. The achieved androgen levels obtained were well below male levels and only in the lower part of normal female levels. It therefore remains possible that administration of DHEA in a higher dose or testosterone would have induced significant metabolic effects. Our sample size and design has previously been shown to be sufficient to detect significant changes following physiological exposure to GH and cortisol but it remains possible that a larger study population could have revealed subtle but significant effects of DHEA in our patients. Finally, the hydrocortisone substitution in this patient group only poorly imitates normal physiology, which may have interfered with the co-administration of DHEA.

In summary, we did not find any significant acute effects of exogenous DHEA on basal as well as stimulated substrate metabolism in women with adrenal insufficiency. We hypothesize that adrenal androgens play a limited role in the acute regulation of fuel metabolism.

Acknowledgements

J J C is supported by a PhD research fellowship by the University of Århus. Elsebeth Hornemann, Hanne Pedersen and Lone Svendsen are thanked for expert technical help. The study was supported by a grant from the Danish Health Research Council, grant number 9600822 (Århus University—Novo Nordisk Center for Research in Growth and Regeneration). The microdialysis catheters and other utensils were generously supplied by Roche Diagnostics.

References


2 Labrie F, Belanger A, Cusan I & Candus B. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrine and DHEA metabolism. Journal of Clinical Endocrinology and Metabolism 1997 82 2403–2409.


16 Gravholt CH, Møller N, Jensen MD, Christiansen JS & Schmitz O. Physiological levels of glucagon do not influence lipolysis in abdominal adipose tissue as assessed by microdialysis. *Journal of Clinical Endocrinology and Metabolism* 2001 86 2085–2089.


Received 7 July 2004
Accepted 23 September 2004

www.eje-online.org